ExchangeDEX+

Buy Crypto Markets Spot FuturesGOLD Earn Event Center

BEIJING, Dec. 18, 2025 /PRNewswire/ — Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfullyBEIJING, Dec. 18, 2025 /PRNewswire/ — Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully

Syneron Bio Closes Nearly $100M in Series A and A+ Rounds

Author: AI Journal

Source: AI Journal

2025/12/19 09:15

2 min read

BIO$0,02731+0,62%

TOP$0,0000951--%

BEIJING, Dec. 18, 2025 /PRNewswire/ — Syneron Bio, an macrocyclic peptide drug discovery company driven by intelligent high-throughput platform, has successfully completed its Series A and A+ financing rounds, raising close to USD 100 million in total. Top-tier investors participated in the round, including AstraZeneca, AZ-CICC Healthcare Investment Fund, Pfizer Biotech Development Investment Fund, GL Ventures, 5Y Capital, Sinovation Capital, Lenovo Capital, Gree Capital and KHK fund.

Dr. Xiao Zhang, Founder and CEO of Syneron Bio, commented:
“We are honored to receive the recognition and support of leading global pharmaceutical companies and top-tier investment institutions. This financing will significantly strengthen the development of our intelligent high-throughput macrocyclic peptide development platform, Synova, and provide the resources needed to advance multiple pipelines toward clinical stages.”

About Syneron Bio

Syneron Bio is a biotech company dedicated to the development of next-generation macrocyclic peptide therapeutics, employing its proprietary Synova platform. The company has built a robust pipeline targeting oncology and chronic diseases. With a team experienced in drug development and data science, Syneron Bio has completed multiple rounds of equity financing in less than three years, backed by multiple leading venture capital funds.

Company：Syneron Bio
Contact Person: Corrine.Chan
Email: corrine.chan@synerontech.com
Telephone: 1801606886
City: Beijing

View original content:https://www.prnewswire.com/news-releases/syneron-bio-closes-nearly-100m-in-series-a-and-a-rounds-302646092.html

SOURCE Syneron Bio

Market Opportunity

BIO Protocol Price(BIO)

$0,02731

$0,02731$0,02731

+0,84%

USD

BIO Protocol (BIO) Live Price Chart

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.